Made for conjugation

Mobius® ADC Reactor with Single-Use Technology

Making the switch to single-use for conjugation

While there is a general shift toward single-use technologies among mAb manufacturers, the adoption for Antibody Drug Conjugate manufacturing steps is not as common. Facilities are hesitant to adopt single-use methods because they have concerns about compatibility, quality and safety. But sticking with stainless steel or glass manufacturing methods has many limitations.

The limitations of stainless steel or glass manufacturing methods

- Extensive cleaning and sterilization between runs
- Underutilized equipment and costly facility expansions
- Resource intensive methods
- Negative environmental impact
- Difficult to respond quickly to changing demands

The **Mobius® ADC Reactor** allows for flexible manufacturing that reduces risk, is compatible with your existing workflow, and reduces waste for maximum efficiency.



Ultimus® Film

Superior film resistance with Ultimus film

- No drip no splash with reagent dip tubes
- Preserved product quality with gentle mAb addition via side port

Flexible Manufacturing

10 L 100 L 500 L

Linear Scale-up with the Mobius® ADC Reactor

Accommodates varying batch sizes, adapting to ADC development phases, and enables smooth scale-up.

30% **Risk Reduction**

95% **Potent Liquid Waste Reduction**

70% **Increase in Efficiency**

Learn more about the **Mobius® ADC Reactor**
SigmaAldrich.com/ADC-reactor

MilliporeSigma is the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany.

Lit No. MS_FL13584EN 06/2024 V1.0

Millipore®
Expert Pharm/BioPharm Products & CTDMO Services